Literature DB >> 15197388

Malignant pleural mesothelioma.

Harvey I Pass1, Nicholas Vogelzang, Steven Hahn, Michele Carbone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15197388     DOI： 10.1016/j.currproblcancer.2004.04.001

Source DB:  PubMed          Journal:  Curr Probl Cancer        ISSN： 0147-0272            Impact factor:   3.187


× No keyword cloud information.
  24 in total

1.  Coarse pleural calcification in a mesothelioma patient raises the possibility of a rare tumour subtype: osteoblastic sarcomatoid mesothelioma.

Authors:  A M Mortimer; J Rowlands; P Murphy
Journal:  Br J Radiol       Date:  2011-05       Impact factor: 3.039

2.  [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma].

Authors:  A Scherpereel; P Astoul; P Baas; T Berghmans; H Clayson; P de Vuyst; H Dienemann; F Galateau-Salle; C Hennequin; G Hillerdal; C Le Pe'choux; L Mutti; J-C Pairon; R Stahel; P van Houtte; J van Meerbeeck; D Waller; W Weder
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-10

3.  Molecular biology of malignant mesothelioma.

Authors:  Yoshitaka Sekido
Journal:  Environ Health Prev Med       Date:  2008-02-28       Impact factor: 3.674

4.  Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.

Authors:  Najmunnisa Nasreen; Nazli Khodayari; Kamal A Mohammed
Journal:  Am J Cancer Res       Date:  2012-02-15       Impact factor: 6.166

5.  LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade.

Authors:  I Tanaka; H Osada; M Fujii; A Fukatsu; T Hida; Y Horio; Y Kondo; A Sato; Y Hasegawa; T Tsujimura; Y Sekido
Journal:  Oncogene       Date:  2013-12-16       Impact factor: 9.867

6.  Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma.

Authors:  Liyan Huang; Muyan Cai; Xu Zhang; Fang Wang; Likun Chen; Meng Xu; Ke Yang; Zhen Chen; Xiaokun Wang; Liwu Fu
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

7.  Inhibition of mesothelioma cancer stem-like cells with adenovirus-mediated NK4 gene therapy.

Authors:  Xu-Bin Deng; Li Xiao; Yue Wu; Fang Jin; Brooke Mossman; Joseph R Testa; Guang-Hui Xiao
Journal:  Int J Cancer       Date:  2014-12-27       Impact factor: 7.396

8.  Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed.

Authors:  Pietro Bertino; Camillo Porta; Dario Barbone; Serena Germano; Sara Busacca; Sabrina Pinato; Giancarlo Tassi; Roberto Favoni; Giovanni Gaudino; Luciano Mutti
Journal:  Thorax       Date:  2007-02-20       Impact factor: 9.139

Review 9.  Malignant pleural mesothelioma: current and future perspectives.

Authors:  Konstantinos Porpodis; Paul Zarogoulidis; Efimia Boutsikou; Antonis Papaioannou; Nikolaos Machairiotis; Kosmas Tsakiridis; Nikolaos Katsikogiannis; Bojan Zaric; Branislav Perin; Haidong Huang; Ioanna Kougioumtzi; Dionysios Spyratos; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2013-09       Impact factor: 2.895

Review 10.  Management options for malignant pleural mesothelioma: clinical and cost considerations.

Authors:  Ranjit K Goudar
Journal:  Drugs       Date:  2007       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.